# The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients

> **NCT05063682** · PHASE1 · UNKNOWN · sponsor: **Chembrain LTD** · enrollment: 10 (actual)

## Conditions studied

- Glioblastoma
- Glioblastoma Multiforme
- Glioma, Malignant

## Interventions

- **BIOLOGICAL:** EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes

## Key facts

- **NCT ID:** NCT05063682
- **Lead sponsor:** Chembrain LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-15
- **Primary completion:** 2023-10
- **Final completion:** 2023-10
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2021-10-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05063682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05063682, "The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05063682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*